Boehringer Ingelheim expands Vienna location

The international pharmaceutical company Boehringer Ingelheim continues to invest in its Vienna location. Yesterday morning, vice mayor Renate Brauner opened a new administration building in the Boehringer Ingelheim Regional Center Vienna in Meidling. The building has space for approximately 240 employees and costs 17 Million euros. In addition, the company is currently constructing a new laboratory building for cancer research on the site. The planned end of construction is fall 2015 and the costs will be around 20 Million euros. Additional projects are in planning.

Boehringer Ingelheim RCV is responsible for the business activities of the company in more than 30 countries in Central and Eastern Europe, Central Asia as well as Israel and Switzerland. "The office building opened today has around 240 workplaces. In addition, we started the construction of an ultra-modern research building a few months ago," reported Philipp von Lattorff, Country Managing Director, Boehringer Ingelheim RCV, on the occasion of the opening. "Even more investment projects will be awaiting a decision soon. These investments are a major vote of confidence of the owning families and Board of Managing Directors in the quality of the work done in Vienna," says Lattorff.
Crucial for the investments in the Vienna location were a stable political and economic environment as well as stable framework requirements, such as research funding. Von Lattorff thanked the representatives of the city of Vienna for measures already in place to reduce the red tape and support the implementation of projects.

Boehringer Ingelheim Regional Center Vienna
The Boehringer Ingelheim Regional Center Vienna is responsible for the business with prescription medicinesconsumer healthcare as well as veterinary products from Boehringer Ingelheim in Austria as well as in more than 30 countries in the region of Central and Eastern Europe, Central Asia as well as Israel and Switzerland. In addition, all of the clinical research in the region is coordinated by Vienna. Vienna is the center for cancer research as well as one site for biopharmaceutical research, development and production in the international corporation. Boehringer Ingelheim is also committed to basic research and is represented here with the Research Institute of Molecular Pathology, in  Vienna (IMP). Boehringer Ingelheim is therefore one of the most research-intensive pharmaceutical companies in Austria. Overall, the regional center in Vienna achieved a total revenue of 914.5 Million Euros in the 2013 fiscal year and employed 3,273 employees in the region.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)